MedTrace Logo

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

NCT05966740 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-09-04

No results posted yet for this study

Summary

The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

  • Children's Hospital Acquired Thrombosis consortium

    collaborator UNKNOWN

  • Boehringer Ingelheim

    lead INDUSTRY

Eligibility

Min Age
3 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2025-04-28
Completion
2025-04-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05966740 on ClinicalTrials.gov